Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Enzo Biochem, Inc. (ENZ): Are Hedge Funds Right About This Stock?

Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips on the charts, usually don’t make them change their opinion towards a company. This time it may be different. During the third quarter we observed increased volatility and small-cap stocks underperformed the market. Hedge fund investor letters indicated that they are cutting their overall exposure, closing out some position and doubling down on others. Let’s take a look at the hedge fund sentiment towards Enzo Biochem, Inc. (NYSE:ENZ) to find out whether it was one of their high conviction long-term ideas.

Amid a relatively high valuation (the stock is trading at around 38 times earnings) Enzo Biochem has seen a decrease in support from the world’s most elite money managers in recent months. At the end of this article we will also compare ENZ to other stocks, including Information Services Group, Inc. (NASDAQ:III), Rosetta Stone Inc (NYSE:RST), and Owens Realty Mortgage Inc (NYSEMKT:ORM) to get a better sense of its popularity.

Follow Enzo Biochem Inc (NYSE:ENZ)
Trade (NYSE:ENZ) Now!

At the moment there are a multitude of methods shareholders use to assess their stock investments. Some of the most under-the-radar methods are hedge fund and insider trading activity. Our researchers have shown that, historically, those who follow the top picks of the best fund managers can outpace the broader indices by a superb margin (see the details here).

With all of this in mind, we’re going to take a peek at the recent action surrounding Enzo Biochem, Inc. (NYSE:ENZ).

How have hedgies been trading Enzo Biochem, Inc. (NYSE:ENZ)?

At the Q3’s end, a total of 10 of the hedge funds tracked by Insider Monkey were long this stock, a change of -9% from the second quarter. With the smart money’s sentiment swirling, there exists an “upper tier” of key hedge fund managers who were upping their stakes significantly (or already accumulated large positions).

When looking at the institutional investors followed by Insider Monkey, Jim Simons’ Renaissance Technologies has the number one position in Enzo Biochem, Inc. (NYSE:ENZ), worth close to $3.5 million, accounting for less than 0.1% of its total 13F portfolio. The second most bullish fund is Millennium Management, led by Israel Englander, holding a $1.7 million position; the fund has less than 0.1% of its 13F portfolio invested in the stock. Some other members of the smart money that hold long positions contain Philip Hempleman’s Ardsley Partners, Mark Coe’s Coe Capital Management, and D. E. Shaw’s D E Shaw.

Because Enzo Biochem, Inc. (NYSE:ENZ) has faced a decline in interest from hedge fund managers, logic holds that there is a sect of funds that slashed their positions entirely by the end of the third quarter. At the top of the heap, Ben Levine, Andrew Manuel and Stefan Renold’s LMR Partners cut the biggest stake of the 700 funds watched by Insider Monkey, totaling about $0.1 million in stock, and Cliff Asness’ AQR Capital Management was right behind this move, as the fund dropped about $0.1 million worth. These bearish behaviors are intriguing to say the least, as total hedge fund interest dropped by 1 funds by the end of the third quarter.

Let’s go over hedge fund activity in other stocks similar to Enzo Biochem, Inc. (NYSE:ENZ). We will take a look at Information Services Group, Inc. (NASDAQ:III), Rosetta Stone Inc (NYSE:RST), Owens Realty Mortgage Inc (NYSEMKT:ORM), and Rightside Group Ltd (NASDAQ:NAME). This group of stocks’ market values are closest to ENZ’s market value.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
III 5 8022 -5
RST 12 81507 1
ORM 4 15055 0
NAME 7 10929 -1

As you can see these stocks had an average of 7 hedge funds with bullish positions and the average amount invested in these stocks was $29 million. That figure was $7 million in ENZ’s case. Rosetta Stone Inc (NYSE:RST) is the most popular stock in this table. On the other hand, Owens Realty Mortgage Inc (NYSEMKT:ORM) is the least popular one with only 4 bullish hedge fund positions. Enzo Biochem, Inc. (NYSE:ENZ) is not the most popular stock in this group, but hedge fund interest is still above average. This is a slightly positive signal, but we’d rather spend our time researching stocks that hedge funds are piling on. In this regard RST might be a better candidate to consider a long position.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.